DOP2022000179A - Composiciones farmacéuticas de sales de éster de colina de ácido lipoico y métodos de tratamiento usando las mismas - Google Patents
Composiciones farmacéuticas de sales de éster de colina de ácido lipoico y métodos de tratamiento usando las mismasInfo
- Publication number
- DOP2022000179A DOP2022000179A DO2022000179A DO2022000179A DOP2022000179A DO P2022000179 A DOP2022000179 A DO P2022000179A DO 2022000179 A DO2022000179 A DO 2022000179A DO 2022000179 A DO2022000179 A DO 2022000179A DO P2022000179 A DOP2022000179 A DO P2022000179A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methods
- pharmaceutical compositions
- lipoic acid
- treatment
- same
- Prior art date
Links
- 229960001231 choline Drugs 0.000 title abstract 2
- 235000019136 lipoic acid Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960002663 thioctic acid Drugs 0.000 title abstract 2
- AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical group OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 title 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 choline ester Chemical class 0.000 abstract 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020079271 | 2020-03-13 | ||
| US202063013836P | 2020-04-22 | 2020-04-22 | |
| PCT/IB2021/052092 WO2021181361A1 (en) | 2020-03-13 | 2021-03-12 | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2022000179A true DOP2022000179A (es) | 2022-09-30 |
Family
ID=75108681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000179A DOP2022000179A (es) | 2020-03-13 | 2022-09-07 | Composiciones farmacéuticas de sales de éster de colina de ácido lipoico y métodos de tratamiento usando las mismas |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11135239B1 (enExample) |
| EP (1) | EP4118079A1 (enExample) |
| JP (2) | JP7041298B2 (enExample) |
| KR (1) | KR20220146561A (enExample) |
| CN (2) | CN113387923A (enExample) |
| AU (1) | AU2021235563A1 (enExample) |
| BR (1) | BR112022018043A2 (enExample) |
| CA (1) | CA3175077A1 (enExample) |
| CO (1) | CO2022012653A2 (enExample) |
| CR (1) | CR20220449A (enExample) |
| DO (1) | DOP2022000179A (enExample) |
| EC (1) | ECSP22069611A (enExample) |
| IL (1) | IL295378A (enExample) |
| JO (1) | JOP20220211A1 (enExample) |
| MX (1) | MX2022011206A (enExample) |
| PE (1) | PE20230242A1 (enExample) |
| TW (1) | TWI768760B (enExample) |
| WO (1) | WO2021181361A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118634218A (zh) | 2023-05-24 | 2024-09-13 | 温州医科大学附属眼视光医院 | 一种有效延缓及治疗近视的药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5520920A (en) | 1978-07-31 | 1980-02-14 | Honda Motor Co Ltd | Device for absorbing twisting vibration of drive system |
| US8647612B2 (en) | 2008-03-05 | 2014-02-11 | Encore Health, Llc | Dithiol compounds, derivatives, and treatment of presbyopia |
| PE20060259A1 (es) * | 2004-04-27 | 2006-03-25 | Glaxo Group Ltd | Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico |
| DE102006062599B4 (de) | 2006-12-29 | 2018-03-08 | Endress + Hauser Gmbh + Co. Kg | Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung |
| WO2009038656A1 (en) | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
| US9044439B2 (en) | 2008-03-05 | 2015-06-02 | Encore Health, Llc | Low dose lipoic and pharmaceutical compositions and methods |
| WO2009111635A2 (en) | 2008-03-05 | 2009-09-11 | Encore Health, Llc | Dithiol compounds, derivatives, and uses therefor |
| DK2442647T3 (en) * | 2009-06-15 | 2016-05-30 | Encore Health Llc | Dithiolforbindelser, derivatives thereof, and the uses of these |
| EP2442645B1 (en) | 2009-06-15 | 2014-08-27 | Encore Health, Llc | Choline esters |
| CN106455563A (zh) * | 2014-03-03 | 2017-02-22 | 安可视觉公司 | 硫辛酸胆碱酯组合物及使用方法 |
| WO2016126662A1 (en) | 2015-02-03 | 2016-08-11 | Kardiatonos, Inc. | Compounds for the prevention and treatment of vascular disease |
| WO2016164534A1 (en) | 2015-04-09 | 2016-10-13 | Kardiatonos, Inc. | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage |
| US10449209B2 (en) | 2015-04-29 | 2019-10-22 | Arterez, Llc | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage |
| EP3352739B1 (en) * | 2015-09-24 | 2021-10-27 | Novartis AG | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations |
| JOP20190057A1 (ar) * | 2016-09-23 | 2019-03-24 | Encore Vision Inc | تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية |
| CN107089967A (zh) * | 2017-05-12 | 2017-08-25 | 苏州富士莱医药股份有限公司 | 一种r‑硫辛酸胆碱酯卤化物的制备方法 |
| CN106967044B (zh) * | 2017-05-12 | 2019-02-22 | 苏州富士莱医药股份有限公司 | 制备r-硫辛酸胆碱酯卤化物的方法 |
| JP2021512876A (ja) * | 2018-02-05 | 2021-05-20 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 |
| US11158871B2 (en) | 2018-07-18 | 2021-10-26 | GM Global Technology Operations LLC | Fuel cell assembly and a vehicle that utilizes the fuel cell assembly |
| US11985964B2 (en) | 2018-08-03 | 2024-05-21 | Kevin F Lohmeier | Fishing rod holder |
| CN108822077A (zh) | 2018-08-07 | 2018-11-16 | 苏州富士莱医药股份有限公司 | 一种r-硫辛酸胆碱酯卤化物的精制方法 |
| CN108586429A (zh) | 2018-08-07 | 2018-09-28 | 苏州富士莱医药股份有限公司 | R-硫辛酸胆碱酯卤化物的纯化精制方法 |
-
2021
- 2021-03-03 CN CN202110237490.7A patent/CN113387923A/zh active Pending
- 2021-03-08 JP JP2021035929A patent/JP7041298B2/ja active Active
- 2021-03-11 TW TW110108635A patent/TWI768760B/zh not_active IP Right Cessation
- 2021-03-12 CA CA3175077A patent/CA3175077A1/en active Pending
- 2021-03-12 BR BR112022018043A patent/BR112022018043A2/pt not_active Application Discontinuation
- 2021-03-12 WO PCT/IB2021/052092 patent/WO2021181361A1/en not_active Ceased
- 2021-03-12 IL IL295378A patent/IL295378A/en unknown
- 2021-03-12 US US17/199,736 patent/US11135239B1/en active Active
- 2021-03-12 JO JOP/2022/0211A patent/JOP20220211A1/ar unknown
- 2021-03-12 CR CR20220449A patent/CR20220449A/es unknown
- 2021-03-12 EP EP21713132.5A patent/EP4118079A1/en active Pending
- 2021-03-12 MX MX2022011206A patent/MX2022011206A/es unknown
- 2021-03-12 PE PE2022001926A patent/PE20230242A1/es unknown
- 2021-03-12 CN CN202180020651.5A patent/CN115279745A/zh active Pending
- 2021-03-12 AU AU2021235563A patent/AU2021235563A1/en not_active Abandoned
- 2021-03-12 KR KR1020227033130A patent/KR20220146561A/ko not_active Ceased
- 2021-08-31 US US17/463,391 patent/US11590158B2/en active Active
- 2021-12-20 JP JP2021206074A patent/JP2022058376A/ja active Pending
-
2022
- 2022-09-06 CO CONC2022/0012653A patent/CO2022012653A2/es unknown
- 2022-09-06 EC ECSENADI202269611A patent/ECSP22069611A/es unknown
- 2022-09-07 DO DO2022000179A patent/DOP2022000179A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3175077A1 (en) | 2021-09-16 |
| JOP20220211A1 (ar) | 2023-01-30 |
| US20210283171A1 (en) | 2021-09-16 |
| TWI768760B (zh) | 2022-06-21 |
| TW202140435A (zh) | 2021-11-01 |
| IL295378A (en) | 2022-10-01 |
| CO2022012653A2 (es) | 2022-09-09 |
| AU2021235563A1 (en) | 2022-09-22 |
| US11590158B2 (en) | 2023-02-28 |
| CR20220449A (es) | 2022-10-12 |
| ECSP22069611A (es) | 2022-10-31 |
| US11135239B1 (en) | 2021-10-05 |
| JP2021147392A (ja) | 2021-09-27 |
| BR112022018043A2 (pt) | 2022-10-18 |
| CN113387923A (zh) | 2021-09-14 |
| CN115279745A (zh) | 2022-11-01 |
| US20210393671A1 (en) | 2021-12-23 |
| JP2022058376A (ja) | 2022-04-12 |
| PE20230242A1 (es) | 2023-02-07 |
| WO2021181361A1 (en) | 2021-09-16 |
| MX2022011206A (es) | 2022-09-19 |
| KR20220146561A (ko) | 2022-11-01 |
| JP7041298B2 (ja) | 2022-03-23 |
| EP4118079A1 (en) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19021312A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos | |
| CL2022000603A1 (es) | Inhibidores prmt5 cooperativos de mta | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| CL2019002664A1 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados. | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| GT201400281A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| MX2018015302A (es) | Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos. | |
| PE20151501A1 (es) | Inhibidores de prmt5 y sus usos | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| UY33270A (es) | Sales cristalinas de un potente inhibidor del hcv | |
| CL2024001364A1 (es) | Inhibidores de pi3k-alfa y métodos para su producción y uso | |
| UY39517A (es) | Inhibidores de la btk | |
| MX377532B (es) | Sales y formas sólidas de un antibiótico de monobactam. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| UY39390A (es) | Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
| CL2020002519A1 (es) | Composiciones de erenumab y usos de las mismas | |
| MX2021013888A (es) | Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas. | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| DOP2022000179A (es) | Composiciones farmacéuticas de sales de éster de colina de ácido lipoico y métodos de tratamiento usando las mismas | |
| CO2021011042A2 (es) | Sales de sulcardina | |
| ES2537221B2 (es) | SALES DE PIRIDAZINO[2,3-a]PIRROLO[2,1-c]QUINOXALINIO PARA EL TRATAMIENTO DE INFECCIONES POR LEISHMANIA Y ENFERMEDADES EN LAS QUE ESTÁ IMPLICADA LA PROTEÍNA TIROSINA FOSFATASA 1B | |
| MX2021009423A (es) | Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). |